צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Lexicon Corp (LXRX)
Lexicon Pharmaceuticals (LXRX) is focusing on the independent market launch of its cardiology drug while ignoring merger and acquisition deals. This TTM annual sales growth chart helps identify a demand reversal, where the -46.10 mark reflects the latest data. Success depends on Inpefa sales rates, insurance coverage, and costs, as well as physician confidence and the availability of subsidized quotas.
פילוחי נתונים אנליטיים מרוכזים עבור Lexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals (LXRX) expansion into the commercial market through the growth of its sales representative workforce directly impacts drug sales dynamics. This indicator measures the percentage deviation of current trailing 12-month total revenue from the same period last year, allowing the historical trend of year-over-year 12-month revenue changes to identify operational slowdowns or business accelerations between quarterly reports.